证券代码：300485 证券简称：赛升药业 公告编号：2025-028 表决结果：赞成 8 票、反对 0 票、弃权 0 票、回避 0 票。 北京赛升药业股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第九次会议 于2025年8月20日在公司会议室召开，本次会议于2025年8月8日以通讯的方式向 所有董事送达了会议通知。应参与会议董事8名，实际参会董事8人，会议由董事 长马骉主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符合《中 华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 1、审议通过《关于公司<2025年半年度报告>及其摘要的议案》 公司《2025 年半年度报告》及《2025 年半年度报告摘要》的编制程序符合 法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何 ...

Group 1 - The core business of Sai Sheng Pharmaceutical is primarily in the pharmaceutical manufacturing sector, accounting for 99.63% of its total revenue for the year 2024 [1] - The company announced a plan to utilize idle funds effectively by investing up to 1.2 billion yuan in financial products, with the aim of increasing financial returns without affecting normal operations [3] - The investment plan is set to be valid for one year from the date of approval at the shareholders' meeting scheduled for August 20, 2025 [3]

Core Viewpoint - The company reported a decline in revenue and a return to profitability in the first half of 2025 compared to the same period in 2024 [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 197 million yuan, representing a year-on-year decrease of 8.4% [2] - The net profit attributable to shareholders for the first half of 2025 was approximately 47.79 million yuan, with a basic earnings per share of 0.1 yuan [2] - In comparison, the revenue for the same period in 2024 was approximately 215 million yuan, with a net loss attributable to shareholders of about 105 million yuan and a basic loss per share of 0.22 yuan [2]

赛升药业公告，2025年上半年营业收入1.97亿元，同比下降8.40%。净利润4778.62万元，上年同期亏损 1.05亿元，同比增长145.45%。 ...

北京赛升药业股份有限公司 2025 年半年度报告全文 北京赛升药业股份有限公司 2025 年半年度报告 2025-032 2025 年 08 月 1 北京赛升药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人马骉、主管会计工作负责人梁东娜及会计机构负责人(会计主 管人员)唐会欣声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司已在本报告"第三节管理层讨论与分析"之"十、公司面临的风险和 应对措施"部分，对可能面临的风险进行详细描述，敬请投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 7 | | 第三节 | 管理层讨论与分析 10 | | 第四节 | 公司治理、环境和社会 29 | | 第五节 | 重要事项 32 | | 第六 ...

Market Overview - The biopharmaceutical sector increased by 0.27% on August 19, with Olin Bio leading the gains [1] - The Shanghai Composite Index closed at 3727.29, down 0.02%, while the Shenzhen Component Index closed at 11821.63, down 0.12% [1] Top Performers - Olin Bio (688319) closed at 31.21, up 12.71% with a trading volume of 275,600 shares and a transaction value of 831 million [1] - Nossland (430047) closed at 28.44, up 11.53% with a trading volume of 211,700 shares and a transaction value of 622 million [1] - Ganli Pharmaceutical (603087) closed at 68.03, up 6.95% with a trading volume of 406,100 shares and a transaction value of 2.793 billion [1] Underperformers - Junshi Biosciences (688180) closed at 45.32, down 3.70% with a trading volume of 210,400 shares and a transaction value of 977 million [2] - ZhiXiangQuanTai (688443) closed at 33.05, down 3.42% with a trading volume of 77,200 shares and a transaction value of 260 million [2] - SanShengGuoJian (688336) closed at 54.10, down 2.50% with a trading volume of 85,900 shares and a transaction value of 477 million [2] Capital Flow - The biopharmaceutical sector saw a net inflow of 250 million from institutional investors, while retail investors experienced a net outflow of 379 million [2][3] - Major stocks like Shenzhou Cell (688520) had a net inflow of 1.39 billion from institutional investors, but a net outflow of 1.08 billion from retail investors [3]

Group 1 - The restructuring protein sector is leading the market with an increase of 3.07% [1] - Key companies in this sector include Kaiyin Technology, which rose by 8.7%, and Saiseng Pharmaceutical, which increased by 7.3% [1] - Other notable performers are Maiwei Biotechnology with a rise of 6.86%, and Baipusais, Hite Biotechnology, and Ruizhi Pharmaceutical, all of which saw gains exceeding 4% [1]

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

证券日报网讯赛升药业8月18日在互动平台回答投资者提问时表示，有关公司在研项目及其具体情况， 请关注公司披露的定期报告及临时公告中的相关内容。药品研发需经多期临床，周期长、风险高，易受 技术、审批、政策等影响，临床研究存在结果不及预期甚至临床研究失败的风险，后续能否获得批准存 在不确定性，敬请注意投资风险。 （文章来源：证券日报） ...

赛升药业（300485.SZ）8月13日在投资者互动平台表示，K11项目已进入Ⅲ期临床试验阶段，启动了70 余家研究中心进行试验，预计年底前完成全部入组，项目正常进行中。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：据传贵公司K11适应症等III期临床试验目标组人数不 足，请问是否如此？ ...